Epidemiologic results raise need for better diagnosis, management of XFS

Article

Exfoliation syndrome (XFS) is a global disease that is important to recognize because of its association with other visual-threatening ocular pathologies, said Alan H. Robin, MD, of the Wilmer Eye Institute at Johns Hopkins University in the United States.

Exfoliation syndrome (XFS) is a global disease that is important to recognize because of its association with other visual-threatening ocular pathologies, said Alan H. Robin, MD, of the Wilmer Eye Institute at Johns Hopkins University in the United States.

Speaking at the World Ophthalmology Congress, Dr. Robin presented his data from an epidemiological study of XFS conducted in southern India that illustrated XFS was a risk factor for glaucoma and highly associated with cataract as well as with vision impairment and blindness from those latter disorders. In that study, about 5,500 subjects underwent a thorough eye examination by ophthalmologists who were carefully trained to identify XFS. A diagnosis of XFS was made in about 6% of the population, and among those individuals, about two-thirds had bilateral disease.

In a multivariate adjusted analysis, XFS increased the risk of glaucoma about sixth-fold. In addition, the study found almost 97% of phakic eyes with XFS had an opacified lens, while 132 eyes had prior cataract surgery. The diagnoses of lens opacification and glaucoma were associated with significant vision loss. Presenting vision was impaired (20/60 or worse) in 91% of eyes with XFS, and 51% were bilaterally blind. After best correction, 60% of eyes with XFS had impaired vision and 26% were bilaterally blind. About 90% of the cases of blindness were accounted for by cataract and 10% by glaucoma, and 60% of patients presenting with glaucoma were blind in both eyes.

"Due to the prevalence of glaucoma and cataract among patients with XFS, we have to be much more careful in identifying individuals with this disease. Leaders in this field need to do better in teaching our residents and colleagues in the community that XFS is found in populations worldwide, that patients with XFS and glaucoma need aggressive care and follow-up, and about methods for improving the outcomes of cataract surgery in these eyes so that we do not create even more blindness," said Dr. Robin.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Related Content
© 2025 MJH Life Sciences

All rights reserved.